Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of cell-based quadrivalent versus trivalent subunit influenza vaccines in children and adolescents
2015-000133-70Phase 3
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza vaccine surface antigen inactivated prepared in cell cultures and influenza vaccine (surface antigen, inactivated, prepared in cell cultures) in influenza (3 arms), sponsored by Novartis. Primary endpoints: Geometric mean titre and Antibody responses according to CBER and CHMP criteria.
02
Drugs
influenza vaccine surface antigen inactivated prepared in cell culturesinfluenza vaccine (surface antigen, inactivated, prepared in cell cultures)
03
Conditions
influenza
Beyond the preview
Go deeper on 2015-000133-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000133-70.